Targeting histone deacetylase 2 in chronic obstructive pulmonary disease treatment

Expert Opinion on Therapeutic Targets

Volumn 9, Issue 6, 2005, Pages 1111-1121

  Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Chromatin; Corticosteroid; Histone acetylation; Histone acetyltransferase (HAT); Histone deacetylase (HDAC); Inflammation; Nuclear factor B (NF B); Theophylline; Transcription factor

Indexed keywords

ACETYLCYSTEINE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CORTICOSTEROID; ENZYME ACTIVATOR; GENE PRODUCT; GLUCOCORTICOID RECEPTOR; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE ACTIVATOR; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PEROXYNITRITE; SMALL INTERFERING RNA; THEOPHYLLINE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ACETYLATION; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; ENZYME ACTIVITY; GENE CONTROL; GENE THERAPY; HEADACHE; HEART ARRHYTHMIA; HIGH THROUGHPUT SCREENING; HUMAN; LOW DRUG DOSE; NAUSEA; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SEIZURE; SMOKING;

ADRENAL CORTEX HORMONES; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPRESSOR PROTEINS;

EID: 28844479963     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.9.6.1111     Document Type: Review

References (86)

1. LOPEZ AD, MURRAY CC: The global burden of disease, 1990-2020. Nat. Med. (1998) 4:1241-1243.
2. BARNES PJ, KLEINERT S: COPD-a neglected disease. Lancet (2004) 364:564-565.
3. BARNES PJ, SHAPIRO SD, PAUWELS RA: Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur. Respir. J. (2003) 22:672-688.
4. BARNES PJ, STOCKLEY RA: COPD: current therapeutic interventions and future approaches. Eur. Respir. J. (2005) 25:1084-1106.
5. ALSAEEDI A, SIN DD, MCALISTER FA: The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am. J. Med. (2002) 113:59-65.
6. BARNES PJ, HANSEL TT: Prospects for new drugs for chronic obstructive pulmonary disease. Lancet (2004) 364:985-996.
7. HOGG JC, CHU F, UTOKAPARCH S et al.: The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. (2004) 350:2645-2653.
8. BARNES PJ: Small airways in COPD. N. Engl. J. Med. (2004) 350:2635-2637.
9. BARNES PJ: Mediators of chronic obstructive pulmonary disease. Pharm. Rev. (2004) 56:515-548.
10. BARNES PJ, ADCOCK IM: Transcription factors and asthma. Eur. Respir. J. (1998) 12:221-234.
11. BARNES PJ, KARIN M: Nuclear factor-kB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. (1997) 336:1066-1071.
12. WRIGHT JG, CHRISTMAN JW: The role of nuclear factor kB in the pathogenesis of pulmonary diseases: implications for therapy. Am. J. Respir. Med. (2003) 2:211-219.
13. BARNES PJ, ADCOCK IM, ITO K: Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur. Respir. J. (2005) 25:552-563.
14. LITTAU VC, BURDICK CJ, ALLFREY VG, MIRSKY SA. The role of histones in the maintenance of chromatin structure. Proc. Natl. Acad. Sci. USA (1965) 54:1204-1212.
15. OGRYZKO VV, SCHILTZ RL, RUSSANOVA V, HOWARD BH, NAKATANI Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell (1996) 87:953-959.
16. ROTH SY, DENU JM, ALLIS CD: Histone acetyltransferases. Ann. Rev. Biochem. (2001) 70:81-120.
17. GAO L, CUETO MA, ASSELBERGS F, ATADJA P: Cloning and functional characterization of HDAC1 1, a novel member of the human histone deacetylase family. J. Biol. Chem. (2002) 277:25748-25755.
18. ITO K, BARNES PJ, ADCOCK IM: Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits IL-1b-induced histone H4 acetylation on lysines 8 and 12. Mol. Cell. Biol. (2000) 20:6891-6903.
19. DE RUIJTER AJ, VAN GENNIP AH, CARON HN, KEMP S, VAN KUILENBURG AB: Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. (2003) 370:737-749.
20. THIAGALINGAM S, CHENG KH, LEE HJ, MINEVA N, THIAGALINGAM A, PONTE JF: Histone deacetylases: unique players in shaping the epigenetic histone code. Ann. N.Y. Acad. Sci. (2003) 983:84-100.
21. PETERSON CL: HDACs at work: everyone doing their part. Mol. Cell (2002) 9:921-922.
22. JONES PL, SHI YB: N-CoR-HDAC corepressor complexes: roles in transcriptional regulation by nuclear hormone receptors. Curr. Top. Microbiol. Immunol. (2003) 274:237-268.
23. FERNANDES I, BASTIEN Y, WAI T et al.: Ligand-dependent nuclear receptor corepressor LCoR functions by histone deacetylase-dependent and -independent mechanisms. Mol. Cell. (2003) 11:139-150.
24. YOSHIDA M, MATSUYAMA A, KOMATSU Y. NISHINO N: From discovery to the coming generation of histone deacetylase inhibitors. Curr. Med. Chem. (2003) 10:2351-2358.
25. COSIO BG, TSAPROUNI L, ITO K, JAZRAWI E, ADCOCK IM, BARNES PJ: Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J. Exp. Med. (2004) 200:689-695.
26. TOMITA K, BARNES PJ, ADCOCK IM: The effect of oxidative stress on histone acetylation and IL-8 release. Biochem. Biophys. Res. Comm. (2003) 301:572-577.
27. ASHBURNER BP, WESTERHEIDE SD, BALDWIN AS, JR.: The p65 (RelA) subunit of NF-kB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol. Cell. Biol. (2001) 21:7065-7077.
28. CHEN L, FISCHLE W, VERDIN E, GREENE WC: Duration of nuclear NF-kB action regulated by reversible acetylation. Science (2001) 293:1653-1657.
29. ZHONG H, MAY MJ, JIMI E, GHOSH S: The phosphorylation status of nuclear NF-kB determines its association with CBP/p300 or HDAC-1. Mol. Cell (2002) 9:625-636.
30. DENU JM: The Sir2 family of protein deacetylases. Curr. Opin. Chem. Biol. (2005).
31. COHEN HY, MILLER C, BITTERMAN KJ et al.: Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science (2004) 305:390-392.
32. BUCK SW, GALLO CM, SMITH JS: Diversity in the Sir2 family of protein deacetylases. J. Leukoc. Biol. (2004) 75:939-950.
33. YEUNG F, HOBERG JE, RAMSEY CS et al.: Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. (2004) 23:2369-2380.
34. PORCU M, CHIARUGI A: The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension. Trends Pharmacol. Sci. (2005) 26:94-103.
35. ITO K, ITO M, ELLIOTT WM et al.: Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N. Engl. J. Med. (2005) 352:1967-1976.
36. MARWICK JA, KIRKHAM PA, STEVENSON CS et al.: Cigarette smoke alters chromatin remodelling and induces pro-inflammatory genes in rat lungs. Am. J. Respir. Cell. Mol. Biol. (2004) 31:633-642.
37. ITO K, LIM S, CARAMORI G, CHUNG KF, BARNES PJ, ADCOCK IM: Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression and inhibits glucocorticoid actions in alveolar macrophages. FASEB J. (2001) 15:1100-1102.
38. RAHMAN I, GILMOUR PS, JIMENEZ LA, MACNEE W: Oxidative stress and TNF-α induce histone acetylation and NF-κB/AP-1 activation in alveolar epithelial cells: potential mechanism in gene transcription in lung inflammation. Mol. Cell. Biochem. (2002) 234-235:239-248.
39. RAHMAN I, MARWICK J, KIRKHAM P: Redox modulation of chromatin remodeling: impact on histone acetylation and deacetylation, NF-κB and pro-inflammatory gene expression. Biochem. Pharmacol. (2004) 68:1255-1267.
40. ITO K, TOMITA T, BARNES PJ, ADCOCK IM: Oxidative stress reduces histone deacetylase (HDAC)2 activity and enhances IL-8 gene expression: role of tyrosine nitration. Biochem. Biophys. Res. Commun. (2004) 315:240-245.
41. MOODIE FM, MARWICK JA, ANDERSON CS et al.: Oxidative stress and cigarette smoke alter chromatin remodeling but differentially regulate NF-kappaB activation and proinflammatory cytokine release in alveolar epithelial cells. FASEB J. (2004).
42. SCHMIDT P, YOUHNOVSKI N, DAIBER A et al.: Specific nitration at tyrosine 430 revealed by high resolution mass spectrometry as basis for redox regulation of bovine prostacyclin synthase. J. Biol. Chem. (2003) 278:12813-12819.
43. BUCHCZYK DP, GRUNE T, SIES H, KLOTZ LO: Modifications of glyceraldehyde-3-phosphate dehydrogenase induced by increasing concentrations of peroxynitrite: early recognition by 20S proteasome. Biol. Chem. (2003) 384:237-241.
44. OSOATA G, ADCOCK IM, BARNES PJ, ITO K: Oxidative stress causes HDAC2 reduction by nitration, ubiquitnylation and proteasomall degradation. Proc. Am. Thorac. Soc. (2005) 2:A755.
45. COSIO BG, JAZRAWI E, ITO K, BARNES PJ, ADCOCK IM: Cigarette smoke decreases steroid responsiveness in monocytes: the role of historic deacetylase. Am. J. Respir. Crit. Care Med. (2003) 167:A804.
46. PAREDI P, KHARITONOV SA, LEAK D, WARD S, CRAMER D, BARNES PJ: Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2000) 162:369-373.
47. MONTUSCHI P, COLLINS JV, CIABATTONI G et al.: Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am. J. Respir. Crit. Care Med. (2000) 162:1175-1177.
48. BIERNACKI WA, KHARITONOV SA, BARNES PJ: Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax (2003) 58:294-298.
49. RAHMAN I, VAN SCHADEWIJK AA, CROWTHER AJ et al.: 4-Hydroxy-2-nonenal, a specific lipid peroxidation product, is elevated in lungs of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2002) 166:490-495.
50. HIGASHIMOTO Y, ELLIOTT WM, BEHZAD AR et al.: Inflammatory mediator mRNA expression by adenovirus E1A-transfected bronchial epithelial cells. Am. J. Respir. Crit. Care Med. (2002) 166:200-207.
51. RETAMALES I, ELLIOTT WM, MESHI B et al.: Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am. J. Respir. Crit. Care Med. (2001) 164:469-473.
52. HOGG JC: Role of latent viral infections in chronic obstructive pulmonary disease and asthma. Am. J. Respir. Crit. Care Med. (2001) 164:S71-S75.
53. YAMADA K, ELLIOTT WM, HAYASHI S, BRATTSAND R, HOGG JC, VITALIS TZ: The effect of latent adenoviral infection on steroid suppression of allergic lung inflammation in guinea pigs. Am. J. Respir. Crit. Care Med. (1999) 157:A516.
54. ITO M, YAMADA K, VITALIS TZ et al.: Latent adenovirus infection decreases histone deacetylase activity in the lungs of ovalbumen-sensitized guinea pigs. Am. J. Respir. Crit. Care Med. (2004) 169:A78.
55. HART L, LIM S, ADCOCK I, BARNES PJ, CHUNG KF: Effects of inhaled corticosteroid therapy on expression and DNA-binding activity of nuclear factor-kB in asthma. Am. J. Respir. Crit. Care Med. (2000) 161:224-231.
56. KEATINGS VM, JATAKANON A, WORSDELL YM, BARNES PJ: Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am. J. Respir. Crit. Care Med. (1997) 155:542-548.
57. CULPITT SV, NIGHTINGALE JA, BARNES PJ: Effect of high dose inhaled steroid on cells, cytokines and proteases in induced sputum in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (1999) 160:1635-1639.
58. LOPPOW D, SCHLEISS MB, KANNIESS F, TAUBE C, JORRES RA, MAGNUSSEN H: In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. Respir. Med. (2001) 95:115-121.
59. CULPITT SY, ROGERS DF, SHAH P et al.: Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2003) 167:24-31.
60. LIM S, ROCHE N, OLIVER BG, MATTOS W, BARNES PJ, FAN CK: Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. regulation by interleukin-10. Am. J. Respir. Crit. Care Med. (2000) 162:1355-1360.
61. BARNES PJ: Corticosteroid resistance in airway disease. Proc. Am. Thorac. Soc. (2004) 1:264-268.
62. BARNES PJ, ITO K, ADCOCK IM: A mechanism of corticosteroid resistance in COPD: inactivation of histone deacetylase. Lancet (2004) 363:731-733.
63. MONTUSCHI P, CIABATTONI G, CORRADI M et al.: Increased 8-Isoprostane, a marker of oxidative stress, in exhaled condensates of asthmatic patients. Am. J. Respir. Crit. Care Med. (1999) 160:216-220.
64. BARALDI E, CARRARO S, ALINOVI R et al.: Cysteinyl leukotrienes and 8-isoprostane in exhaled breath condensate of children with asthma exacerbations. Thorax (2003) 58:505-509.
65. CARAMORI G, PAPI A: Oxidants and asthma. Thorax (2004) 59-170-173.
66. YAMADA K, ELLIOTT WM, BRATTSAND R, VALEUR A, HOGG JC, HAYASHI S: Molecular mechanisms of decreased steroid responsiveness induced by latent adenoviral infection in allergic lung inflammation. J. Allergy Clin. Immunol. (2002) 109:35-42.
67. CHALMERS GW, MACLEOD KJ, THOMSON L, LITTLE SA, MCSHARRY C, THOMSON NC: Smoking and airway inflammation in patients with mild asthma. Chest (2001) 120:1917-1922.
68. CHAUDHURI R, LIVINGSTON E, MCMAHON AD, THOMSON L, BORLAND W, THOMSON NC: Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am. J. Respir. Crit. Care Med. (2003) 168:1265-1266.
69. THOMSON NC, SPEARS M: The influence of smoking on the treatment response in patients with asthma. Curr. Opin. Allergy Clin. Immunol. (2005) 5:57-63.
70. MURAHIDY A, ITO M, ADCOCK IM, BARNES PJ, ITO K: Reduction is histone deacetylase expression and activity in smoking asthmatics: a mechanism of steroid resistance. Proc. Am. Thorac. Soc. (2005) 2:A889.
71. BARNES PJ: Theophylline: new perspectives on an old drug. Am. J. Respir. Crit. Care Med. (2003) 167:813-818.
72. ITO K, LIM S, CARAMORI G, COSIO B, CHUNG KF, ADCOCK IM, BARNES PJ: A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc. Natl. Acad. Sci. USA (2002) 99:8921-8926.
73. CULPITT S, MAZIAK W, LOUKIDES S, KELLER A, BARNES PJ: Effect of theophylline on induced sputum inflammatory indices in COPD patients. Am. J. Respir. Crit. Care Med. (1997) 157:A797.
74. CULPITT SV, DE MATOS C, RUSSELL RE, DONNELLY LE, ROGERS DF, BARNES PJ: Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in COPD. Am. J. Respir. Crit. Care Med. (2002) 165:1371-1376.
75. BARNES PJ: The role of theophylline in severe asthma. Eur. Respir. Rev. (1996) 6(34):154S-159S.
76. ACHARYA MR, SPARREBOOM A, VENITZ J, FIGG WD: Rational development of histone deacetylase inhibitors as anti-cancer agents: a review. Mol. Pharmacol. (2005) 68:917-932.
77. PARK JH, JUNG Y, KIM TY et al.: Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin. Cancer Res. (2004) 10:5271-5281.
78. VANNINI A, VOLPARI C, FILOCAMO G et al.: Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl. Acad. Sci. USA (2004) 101:15064-15069.
79. TSAPROUNI L, ITO K, BARNES PJ, ADCOCK IM: Theophylline induction of histone deacetylase (HDAC)2 activity requires p38 MAP kinase. Am. J. Respir. Crit. Care Med. (2004) 169:A853.
80. FINAN PM, THOMAS MJ: P13-kinase inhibition: a therapeutic target for respiratory disease. Biochem. Soc. Trans. (2004) 32:378-382.
81. BOWLER RP, BARNES PJ, CRAPO JD: The role of oxidative stress in chronic obstructive pulmonary disease. J. COPD (2004) 2:255-277.
82. DECRAMER M, RUTTEN-VAN MOLKEN M, DEKHUIJZEN PN et al.: Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet (2005) 365:1552-1560.
83. CUZZOCREA S, RILEY DP, CAPUTI AP, SALVEMINI D: Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion Injury. Pharmacol. Rev. (2001) 53:135-159.
84. HANSEL TT, KHARITONOV SA, DONNELLY LE et al.: A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics. FASEB J. (2003) 17:1298-1300.
85. MASSARO D, MASSARO GD, CLERCH LB: Noninvasive delivery of small inhibitory RNA and other reagents to pulmonary alveoli in mice. Am. J. Physiol. Lung Cell Mol. Physiol. (2004) 287:L1066-L1070.
86. ZHANG Y, SHAN P, JIANG D et al.: Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. J. Biol. Chem. (2004) 279:10677-10684.